Curanex Pharmaceuticals (CURX) Registration Filing summary

Company overview and business model

• Focuses on discovering, developing, and commercializing innovative botanical drugs for inflammatory diseases, leveraging a proprietary platform for identifying and optimizing anti-inflammatory compounds from medicinal plants.

• Lead candidate, Phyto-N, is a proprietary botanical extract with a history of use in Chinese traditional medicine, targeting multiple indications including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout.

• Business model anticipates revenue from product sales, collaborations, licensing, and research grants, with initial focus on regulatory approval and commercialization of Phyto-N.

• Company transitioned from health products to pharmaceutical R&D in 2023, acquiring key IP assets and preclinical data from a related entity, Duraviva.

Financial performance and metrics

• No revenue generated in 2023 or 2024 due to focus on R&D; net loss of $361,506 in 2024, up from $19,198 in 2023, driven by increased G&A, IPO costs, and impairment charges.

• Cash and cash equivalents as of December 31, 2024, were $148,891, bolstered by a $730,000 asset purchase from Duraviva and a $200,000 loan from a founder.

• Total shareholders' equity at year-end 2024 was $503,360; accumulated deficit was $622,449.

• Company estimates over $150 million will be required to execute its full business plan through FDA approval and product launch.

Use of proceeds and capital allocation

• Net proceeds of approximately $8 million (or $9.34 million if over-allotment is exercised) expected from IPO, based on a $5.00/share midpoint.

• Proceeds allocated: 25.1% for GLP toxicology and pharmacokinetic studies and IND preparation, 12.6% for manufacturing clinical trial material, 37.7% for Phase I clinical trial in ulcerative colitis, and 24.7% for working capital and general purposes.

• Management has broad discretion over use of proceeds and may reallocate funds as needed.